Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group

Presbyterian University Hospital, Pittsburgh, Pennsylvania 15213.

OBJECTIVES. The purpose of this study was to determine whether digoxin is effective in patients with chronic, stable mild to moderate heart failure. BACKGROUND. Digoxin has been a traditional therapy in heart failure, but methodologic limitations in earlier studies have prevented definitive conclusions regarding its efficacy. METHODS. Withdrawal of digoxin (placebo group, n = 46) or its continuation (digoxin group, n = 42) was performed in a prospective, randomized, double-blind, placebo-controlled multicenter trial of patients with chronic, stable mild to moderate heart failure secondary to left ventricular systolic dysfunction who had normal sinus rhythm and were receiving long-term treatment with diuretic drugs and digoxin. RESULTS. Patients withdrawn from digoxin therapy showed worsened maximal exercise capacity (median change in exercise time -96 s) compared with that of patients who continued to receive digoxin (change in exercise time +4.5 s) (p = 0.003). Patients withdrawn from digoxin therapy showed an increased incidence of treatment failures (p = 0.039) (39%, digoxin withdrawal group vs. 19%, digoxin maintenance group) and a decreased time to treatment failure (p = 0.037). In addition, patients who continued to receive digoxin had a lower body weight (p = 0.044) and heart rate (p = 0.003) and a higher left ventricular ejection fraction (p = 0.016). CONCLUSIONS. These data provide strong evidence of the clinical efficacy of digoxin in patients with normal sinus rhythm and mild to moderate chronic heart failure secondary to systolic dysfunction who are treated with diuretics.

This article has been cited by other articles:

				M. J. Ratain, T. Eisen, W. M. Stadler, K. T. Flaherty, S. B. Kaye, G. L. Rosner, M. Gore, A. A. Desai, A. Patnaik, H. Q. Xiong, et al. Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma J. Clin. Oncol., June 1, 2006; 24(16): 2505 - 2512. [Abstract] [Full Text] [PDF]

				M. Gheorghiade, D. J. van Veldhuisen, and W. S. Colucci Contemporary Use of Digoxin in the Management of Cardiovascular Disorders Circulation, May 30, 2006; 113(21): 2556 - 2564. [Full Text] [PDF]

				A. Ahmed, M. W. Rich, T. E. Love, D. M. Lloyd-Jones, I. B. Aban, W. S. Colucci, K. F. Adams, and M. Gheorghiade Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial Eur. Heart J., January 2, 2006; 27(2): 178 - 186. [Abstract] [Full Text] [PDF]

				J. B. Young Whither Withering's Legacy?: Digoxin's Role in Our Contemporary Pharmacopeia for Heart Failure J. Am. Coll. Cardiol., August 2, 2005; 46(3): 505 - 507. [Full Text] [PDF]

				L. G. Olsson, K. Swedberg, A. L. Clark, K. K. Witte, and J. G.F. Cleland Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review Eur. Heart J., April 2, 2005; 26(8): 778 - 793. [Abstract] [Full Text] [PDF]

				P. C. Burger and H. B.-L. Rocca Pharmacotherapy of Congestive Heart Failure in Elderly Patients Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2005; 10(2): 85 - 94. [Abstract] [PDF]

				A. T. Yan, R. T. Yan, and P. P. Liu Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials Ann Intern Med, January 18, 2005; 142(2): 132 - 145. [Abstract] [Full Text] [PDF]

				W. E Cayley Jr Digoxin in chronic heart failure Fam. Pract., August 1, 2004; 21(4): 469 - 472. [Full Text] [PDF]

				S. H. Rahimtoola Digitalis Therapy for Patients in Clinical Heart Failure Circulation, June 22, 2004; 109(24): 2942 - 2946. [Full Text] [PDF]

				M. Gheorghiade, K. F. Adams Jr, and W. S. Colucci Digoxin in the Management of Cardiovascular Disorders Circulation, June 22, 2004; 109(24): 2959 - 2964. [Full Text] [PDF]

				D B McKenzie and A J Cowley Drug therapy in chronic heart failure Postgrad. Med. J., November 1, 2003; 79(937): 634 - 642. [Abstract] [Full Text] [PDF]

				K Kjeldsen, A Norgaard, and M Gheorghiade Myocardial Na,K-ATPase: the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure Cardiovasc Res, September 1, 2002; 55(4): 710 - 713. [Abstract] [Full Text] [PDF]

				B Swynghedauw and D Charlemagne What is wrong with positive inotropic drugs? Lessons from basic science and clinical trials Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D43 - D49. [Abstract] [PDF]

				K. F. Adams Jr, M. Gheorghiade, B. F. Uretsky, J. H. Patterson, T. A. Schwartz, and J. B. Young Clinical benefits of low serum digoxin concentrations in heart failure J. Am. Coll. Cardiol., March 20, 2002; 39(6): 946 - 953. [Abstract] [Full Text] [PDF]

				D. J. van Veldhuisen Low-dose digoxin in patients with heart failure: Less toxic and at least as effective? J. Am. Coll. Cardiol., March 20, 2002; 39(6): 954 - 956. [Full Text] [PDF]

				A. Ahmed, R. M. Allman, and J. F. DeLong Inappropriate Use of Digoxin in Older Hospitalized Heart Failure Patients J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2002; 57(2): M138 - 143. [Abstract] [Full Text]

				M.C. Petrie, C. Berry, S. Stewart, and J.J.V. McMurray Failing ageing hearts Eur. Heart J., November 1, 2001; 22(21): 1978 - 1990. [PDF]

				J. G F Cleland, J. John, J. Dhawan, and A. Clark What is the optimal medical management of ischaemic heart failure? Br. Med. Bull., October 1, 2001; 59(1): 135 - 158. [Abstract] [Full Text] [PDF]

				M. W. Rich, F. McSherry, W. O. Williford, S. Yusuf, and for the Digitalis Investigation Group Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study J. Am. Coll. Cardiol., September 1, 2001; 38(3): 806 - 813. [Abstract] [Full Text] [PDF]

				M. J. Ratain, W. M. Stadler, E. L. Korn, S. G. Arbuck, J. M. Pluda, R. Simon, R. S. Kaplan, and M. C. Christian Clinical Trial Designs for Cytostatic Agents J. Clin. Oncol., June 15, 2001; 19(12): 3154 - 3155. [Full Text] [PDF]

				C Opasich, G.D Pinna, A Mazza, O Febo, R Riccardi, P.G Riccardi, S Capomolla, G Forni, F Cobelli, and L Tavazzi Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice? Eur. Heart J., March 2, 2001; 22(6): 488 - 496. [Abstract] [PDF]

				M. Gomberg-Maitland, D. A. Baran, and V. Fuster Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and the Heart Failure Specialist Arch Intern Med, February 12, 2001; 161(3): 342 - 352. [Abstract] [Full Text] [PDF]

				L. W. Stevenson and R. L. Kormos Mechanical cardiac support 2000: current applications and future trial design: June 15-16, 2000 Bethesda, Maryland J. Am. Coll. Cardiol., January 1, 2001; 37(1): 340 - 370. [Full Text] [PDF]

				E. Lonn and R. McKelvie Regular review: Drug treatment in heart failure BMJ, April 29, 2000; 320(7243): 1188 - 1192. [Full Text]

				H. M. Krumholz, D. W. Baker, C. M. Ashton, S. B. Dunbar, G. C. Friesinger, E. P. Havranek, M. A. Hlatky, M. Konstam, D. L. Ordin, I. L. Pina, et al. Evaluating Quality of Care for Patients With Heart Failure Circulation, March 28, 2000; 101 (12): e122 - e140. [Full Text] [PDF]

				M. W. Rich and R. F. Nease Cost-effectiveness Analysis in Clinical Practice: The Case of Heart Failure Arch Intern Med, August 9, 1999; 159(15): 1690 - 1700. [Abstract] [Full Text] [PDF]

				G. Guyatt A 75-Year-Old Man With Congestive Heart Failure JAMA, June 23, 1999; 281(24): 2321 - 2328. [Full Text] [PDF]

				M. C. Petrie, N. F. Dawson, D. R. Murdoch, A. P. Davie, and J. J. V. McMurray Failure of Women's Hearts Circulation, May 4, 1999; 99(17): 2334 - 2341. [Full Text] [PDF]

				P. J. Hauptman and R. A. Kelly Digitalis Circulation, March 9, 1999; 99(9): 1265 - 1270. [Abstract] [Full Text] [PDF]

				K. M. Williamson, K. A. Thrasher, K. B. Fulton, N. M. A. LaPointe, G. D. Dunham, A. A. Cooper, P. S. Barrett, and J. H. Patterson Digoxin Toxicity: An Evaluation in Current Clinical Practice Arch Intern Med, December 1, 1998; 158(22): 2444 - 2449. [Abstract] [Full Text] [PDF]

				J. B. Young, M. Gheorghiade, B. F. Uretsky, J. H. Patterson, and K. F. Adams Jr. Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials J. Am. Coll. Cardiol., September 1, 1998; 32(3): 686 - 692. [Abstract] [Full Text] [PDF]

				W. T. Abraham Pharmacologic Management of Chronic Heart Failure: A Review Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 168 - 190. [Abstract] [PDF]

				T. A Schmidt and K. Kjeldsen Human myocardial Na,K-ATPase -- quantification, regulation and relation to Ca Cardiovasc Res, February 1, 1998; 37(2): 335 - 345. [Full Text] [PDF]

				J. T. Sullebarger, P. M. D'Ambra, L. C. Clark, L. Thanikarry, and H. L. Fontanet Effect of Digoxin on Ventricular Remodeling and Responsiveness of {beta}-Adrenoceptors in Chronic Volume Overload Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(4): 281 - 290. [Abstract] [PDF]

				K Pardaens, J Van Cleemput, J Vanhaecke, and R H Fagard Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients Heart, December 1, 1997; 78(6): 564 - 568. [Abstract] [Full Text] [PDF]

				A. Matsumori, K. Ono, R. Nishio, H. Igata, B Pharm, T. Shioi, S. Matsui, Y. Furukawa, A. Iwasaki, Y. Nose, et al. Modulation of Cytokine Production and Protection Against Lethal Endotoxemia by the Cardiac Glycoside Ouabain Circulation, September 2, 1997; 96(5): 1501 - 1506. [Abstract] [Full Text]

				The Digitalis Investigation Group The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure N. Engl. J. Med., February 20, 1997; 336(8): 525 - 533. [Abstract] [Full Text] [PDF]

				M. Packer End of the Oldest Controversy in Medicine -- Are We Ready to Conclude the Debate on Digitalis? N. Engl. J. Med., February 20, 1997; 336(8): 575 - 576. [Full Text]

				K. Ogunyankin and B. N. Singh Reflections on Recent Clinical Trials in Patients With Heart Failure and Those With Reduced Ventricular Function Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(3): 147 - 152. [PDF]

				M. R. Costanzo, S. Augustine, R. Bourge, M. Bristow, J. B. O'Connell, D. Driscoll, and E. Rose Selection and Treatment of Candidates for Heart Transplantation : A Statement for Health Professionals From the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association Circulation, December 15, 1995; 92(12): 3593 - 3612. [Abstract] [Full Text]

				COMMITTEE MEMBERS, J. F. WILLIAMS Jr, M. R. BRISTOW, M. B. FOWLER, G. S. FRANCIS, A. GARSON Jr, B. J. GERSH, D. F. HAMMER, M. A. HLATKY, C. V. LEIER, et al. Guidelines for the Evaluation and Management of Heart Failure : Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure) Circulation, November 1, 1995; 92(9): 2764 - 2784. [Full Text]

				M. Gheorghiade, V. B. Hall, G. Jacobsen, M. Alam, H. Rosman, and S. Goldstein Effects of Increasing Maintenance Dose of Digoxin on Left Ventricular Function and Neurohormones in Patients With Chronic Heart Failure Treated With Diuretics and Angiotensin-Converting Enzyme Inhibitors Circulation, October 1, 1995; 92(7): 1801 - 1807. [Abstract] [Full Text]

				S. Zoneraich and D. H. Spodick Bedside Science Reduces Laboratory Art : Appropriate Use of Physical Findings to Reduce Reliance on Sophisticated and Expensive Methods Circulation, April 1, 1995; 91(7): 2089 - 2092. [Full Text]

				J. McMurray and A. Rankin Recent Advances: Cardiology II: Treatment of heart failure and atrial fibrillation and arrhythmias BMJ, December 17, 1994; 309(6969): 1631 - 1635. [Full Text]

				MORE EVIDENCE THAT DIGOXIN IS BENEFICIAL FOR CHF Journal Watch (General), October 8, 1993; 1993(1008): 4 - 4. [Full Text]